AR082139A1 - Preparacion recubiertas con particulas finas - Google Patents

Preparacion recubiertas con particulas finas

Info

Publication number
AR082139A1
AR082139A1 ARP110102459A ARP110102459A AR082139A1 AR 082139 A1 AR082139 A1 AR 082139A1 AR P110102459 A ARP110102459 A AR P110102459A AR P110102459 A ARP110102459 A AR P110102459A AR 082139 A1 AR082139 A1 AR 082139A1
Authority
AR
Argentina
Prior art keywords
oral cavity
isobutyloxyphenyl
cyano
methyl
fine particles
Prior art date
Application number
ARP110102459A
Other languages
English (en)
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45441336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR082139(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of AR082139A1 publication Critical patent/AR082139A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Preparación que no se siente sustancialmente el estímulo en la cavidad oral y en la faringe y que al mismo tiempo se mantiene propiedades de elución y desintegración rápida en la cavidad oral aún mediante la conservación en condiciones de alta temperatura y alta humedad, siendo una tableta de desintegración rápida en la cavidad oral con ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazolcarboxílico como ingrediente activo. Tableta de desintegración rápida en la cavidad oral que contiene las partículas que son las partículas nucleares que contienen ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazolcarboxílico, recubiertas con la capa que contiene copolímero de ácido metacrílico y sobrecubiertas con la capa que contiene azucares solubles en agua.
ARP110102459A 2010-07-09 2011-07-08 Preparacion recubiertas con particulas finas AR082139A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010156874 2010-07-09

Publications (1)

Publication Number Publication Date
AR082139A1 true AR082139A1 (es) 2012-11-14

Family

ID=45441336

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102459A AR082139A1 (es) 2010-07-09 2011-07-08 Preparacion recubiertas con particulas finas

Country Status (24)

Country Link
US (1) US20130101670A1 (es)
EP (1) EP2591781B1 (es)
JP (1) JP5000017B2 (es)
KR (1) KR20130113348A (es)
CN (1) CN102958522B (es)
AR (1) AR082139A1 (es)
AU (1) AU2011274851A1 (es)
BR (1) BR112013000298A2 (es)
CA (1) CA2804874C (es)
CL (1) CL2013000089A1 (es)
CO (1) CO6650363A2 (es)
EC (1) ECSP12012360A (es)
ES (1) ES2644064T3 (es)
MA (1) MA34460B1 (es)
MX (1) MX2013000282A (es)
NZ (1) NZ605562A (es)
PE (1) PE20131064A1 (es)
PH (1) PH12013500032A1 (es)
RU (1) RU2013105456A (es)
TN (1) TN2012000623A1 (es)
TW (1) TW201217001A (es)
UY (1) UY33499A (es)
WO (1) WO2012005365A1 (es)
ZA (1) ZA201300106B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20170306A1 (es) 2010-06-16 2017-05-06 Takeda Pharmaceuticals Usa Inc Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
JP5978216B2 (ja) 2010-09-10 2016-08-24 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド テオフィリンとフェブキソスタットの併用療法のための方法
CN106267220B (zh) * 2015-05-14 2019-06-28 北京科信必成医药科技发展有限公司 愈创甘油醚氢溴酸右美沙芬无水吞服掩味制剂
JP7108384B2 (ja) * 2016-07-13 2022-07-28 日本ケミファ株式会社 ２－［３－シアノ－４－（２－メチルプロポキシ）フェニル］－４－メチルチアゾール－５－カルボン酸の口腔内崩壊錠
GB202001237D0 (en) * 2020-01-29 2020-03-11 Sisteks D O O Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3731699A (en) * 1998-05-18 1999-12-06 Takeda Chemical Industries Ltd. Orally disintegrable tablets
JP4300652B2 (ja) 1998-09-21 2009-07-22 大正製薬株式会社 経口用固形製剤
JP3389205B2 (ja) 1999-06-29 2003-03-24 武田薬品工業株式会社 口腔内速崩壊錠
AP1919A (en) * 2001-11-21 2008-11-13 Eisai R&D Man Co Ltd Preparation compositions containing acid-unstable physiologically active compounds and process for producing the same
JP2005023058A (ja) 2003-06-10 2005-01-27 Lion Corp 咀嚼型医薬製剤用薬物粒子及びその製造方法、並びに薬物粒子を含有する咀嚼型医薬固形製剤及びその製造方法
JP5062872B2 (ja) 2003-08-13 2012-10-31 東和薬品株式会社 不快な味を低減した口腔内崩壊錠剤
CA2619745A1 (en) * 2005-08-18 2007-02-22 Teijin Pharma Limited Tablet with multiple drug-containing sections
PE20070698A1 (es) * 2005-11-14 2007-08-17 Teijin Pharma Ltd Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol
JP5123517B2 (ja) * 2005-11-14 2013-01-23 帝人ファーマ株式会社 アンブロキソール口腔内速崩性錠剤
JP2008050324A (ja) * 2006-08-28 2008-03-06 Ohara Yakuhin Kogyo Kk 苦味遮蔽組成物。
JP5097488B2 (ja) 2006-09-13 2012-12-12 京都薬品工業株式会社 苦味マスキング
PE20170306A1 (es) * 2010-06-16 2017-05-06 Takeda Pharmaceuticals Usa Inc Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa

Also Published As

Publication number Publication date
MA34460B1 (fr) 2013-08-01
ZA201300106B (en) 2013-09-25
US20130101670A1 (en) 2013-04-25
JPWO2012005365A1 (ja) 2013-09-05
ES2644064T3 (es) 2017-11-27
CN102958522B (zh) 2015-12-16
NZ605562A (en) 2013-11-29
WO2012005365A1 (ja) 2012-01-12
MX2013000282A (es) 2013-02-11
EP2591781A1 (en) 2013-05-15
CL2013000089A1 (es) 2013-03-08
UY33499A (es) 2012-01-31
JP5000017B2 (ja) 2012-08-15
CO6650363A2 (es) 2013-04-15
ECSP12012360A (es) 2013-02-28
PH12013500032A1 (en) 2013-02-11
BR112013000298A2 (pt) 2016-05-31
TW201217001A (en) 2012-05-01
RU2013105456A (ru) 2014-08-20
PE20131064A1 (es) 2013-09-23
EP2591781A4 (en) 2014-12-03
EP2591781B1 (en) 2017-09-27
AU2011274851A1 (en) 2013-01-31
CA2804874C (en) 2019-07-23
TN2012000623A1 (en) 2014-04-01
CA2804874A1 (en) 2012-01-12
KR20130113348A (ko) 2013-10-15
CN102958522A (zh) 2013-03-06

Similar Documents

Publication Publication Date Title
WO2012034079A3 (en) Macrolide dosage forms
CO6450625A2 (es) Sistema intrauterino para uso en tratamiento médico
PT3150198T (pt) Composições farmacêuticas de ácido 3-(6-(1-(2,2 difluorobenzo[d][1,3]dioxol-5-il) ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e sua administração
CL2014001729A1 (es) Compuestos derivados de tieno (3,2-d) pirimidina, inhibidores de quinasas; composicion farmaceutica; y su uso en la prevencion o tratamiento de una enfermedad relacionada con quinasas como cancer.
AR082139A1 (es) Preparacion recubiertas con particulas finas
NZ599594A (en) Fast dissolving solid dosage form
PE20130378A1 (es) Formulaciones de apixaban
MX377802B (es) Metodos y composiciones para trastornos del sueño y otros trastornos.
NO20091501L (no) Farmasoytiske sammensetninger
EP2847126A4 (en) BIOGENIC ACTIVE CARBON AND METHOD FOR THE PRODUCTION AND USE THEREOF
NZ619857A (en) A fast dissolving pharmaceutical composition
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
DK2120878T3 (da) Doseringsform indeholdende to aktive farmaceutiske ingredienser i forskellige fysiske former
BR112012004967A2 (pt) forma de dosagem oral, compreendendo pelo menos um agente biologicamente ativo, substâncias auxiliares da formulação e partículas magnetizáveis
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
CL2012002909A1 (es) Procedimiento de preparación de una composición farmacéutica que comprenden a) un centro granulado constituido por granos de principio activo aglomerados en presencia de aglomerante y b) una capa de recubrimiento de dicho centro granulado constituido por matriz grasa; composición farmacéutica; y su uso para administración oral
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
FI20135152L (fi) Farmaseuttinen yhdistelmäkoostumus ja menetelmiä diabeteksen ja metabolisten sairauksien hoidossa
PE20081461A1 (es) Formas solidas de dosificacion farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua
AR081402A1 (es) Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida monohidrato
ES2720869T3 (es) Composiciones farmacéuticas de sevelámero
CO7310526A2 (es) Composición farmaceútica oral en forma de microesferas y proceso de elaboración
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
MX369742B (es) Formulación de liberación modificada.
BR112013010709A2 (pt) derivado de ácido trans-2-decenoico e agente farmacêutico contendo o mesmo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal